# SCHOOL OF BIOMEDICAL SCIENCES RESEARCH ETHICS COMMITTEE MAKERERE UNIVERSITY COLLEGE OF HEALTH SCIENCES REC FORM 101 For Office Use Only REC/A/2007FC EXP XMPT Date received

# APPLICATION TO CONDUCT HEALTH/MEDICAL RESEARCH

This form must be completed by all persons/teams intending to conduct health/medical research in Uganda. Upon completion by the investigator(s) it should be submitted to the School of Biomedical Sciences Research and Ethics committee (SBS-REC). Upon completion of the relevant section by the REC, the form should be submitted to the Secretary, School of Biomedical Sciences Research and Ethics Committee Makerere University College of Health Sciences P. O Box 7072, Kampala. The required registration fee should accompany each application. Irb fee should be deposited on Makerere University Biomedical Science Project A/c in the accounts office.

Protocol Version Number:....

#### APPLICATION FORM CHECKLIST

This checklist was prepared in order to aid investigators in preparing a complete application and to help expedite review by the Ethical Review Committee. Your cooperation in completing it will be greatly appreciated.

PRINCIPAL INVESTIGATOR'S NAME: (SITE PRINCIPAL INVSETIGATOR)				
E-mail:				
Contact number:				
	Application	form duly completed in duplicate.		
	I will submi	t a soft copy of my proposal at application to biomedicalresearch62@gmail.com		
	Two copies	of complete research protocol in general/funding agency format.		
	Two copies	of informed consent forms in English and local language of the study population		
	Two copies	of Drug Brochure or any supplementary information (if applicable).		
	Two copies	of Questionnaire being administered during the study (if applicable).		
	I have made	e a copy of this entire application package for my files.		
	For clinical	trials – I have also submitted an application to NDA (if applicable).		

Signature: Principal Investigator (At S	ite)	Date		
Details of Research Team				
Name of Principal Investigator (P.I)				
Nationality of P.I				
Current Qualifications				
Academic Title				
Institution & Dept.				
Postal address				
E-mail address				
Telephone No.				
Is this research expected to lead to the degree? (Yes/No)	e award of a higher			
If yes, what degree?				
University/Institution where registered	ed			
<b>Co-investigators</b>	Qualifications	Institution/Department		
Names/Supervisors				
Details of the Proposed Research				
Title of proposed research.				
Proposed Starting & Ending Dates				
Performance site(s) in Uganda				
Performance sites (outside Uganda)				
Total number of study investigators				
Budget (state currency)				

Name and address of Funding agency:					
Status of funding:	a)Submitted for fur	nding b)Pending	c)Funded	d)se	elf 🗌
Beginning & Ending Dates of Fundir	ıg				
0 0 0	8				
Collaborating Institutions					
No Name of Institution		Institutional Code			
2 <sup>nd</sup>					
3 <sup>rd</sup>					
4 <sup>th</sup>					
5 <sup>th</sup>					
Population: Proposed inclusion cr. (Check all that apply)	teria T	ype of study (check all th	hat applies)		
Males	$\Box$	ross-sectional/Survey			
Females		econdary data			
		ogram/Project evaluati	ion 🔲		
Vulnerable Groups		linical community trial			
Foetuses		ase control			
Children (Under 12 years of age)		ongitudinal study			
Adolescents (12 – 17 years)		ecord review			
Pregnant women		ourse activity			
Elderly (over 65 years)	U	se of stored samples			
Prisoners					
Cognitively impaired		Other (specify) .			
Hospital patients					
Refugees					
Institutionalized	님				
Other					
Proposed sample size  Reading level of consent document Primary Secondary Tertification  Determination of Risk (Check all that	ary Other (Sp	ecify)			
Does the research involve any of the	11 /			YES	NO
Human exposure to ionizing radiation	<u> </u>				
Human genetics	-			H	HH
Stem Cells				H	H
Fetal tissue or abortus				H	H
Investigational new drug			H	H	
Investigational new device or technique (e.g. therapeutic, diagnostic)				H	Ħ
Existing data available via public archives/sources				H	Ħ
Existing data not available via public archives				Ħ	tH
Observation of public behaviour				H	
Is the information going to be recorded in such a way that subjects can be identified				H	
Does the research deal with sensitive aspects of the subjects behaviour, sexual behavior, alcohol				H	Ħ
use or illegal conduct such as drug us					

Could the information recorded about the individual if it became known outside of the research, place the subject at risk of criminal prosecution or civil liability		
Could the information recorded about the individual if it became known outside of the research, damage the subjects financial standing, reputation and employability?		
Do you consider the proposed research     A) greater than minimal risk     B) minimal risk     C) no risk  Minimal risk is a risk where the probability and magnitude of harm or discomfort anticipated in the proposed greater in and of themselves than those ordinarily encountered in daily life or during the performance of routine psychological examinations or tests. For example the risk of drawing a small amount of blood from a healthy research purposes is no greater than the risk of doing so as part of routine physical examinations.	physical,	
• Do any of the participating investigators and or their immediate families have conflict of intersponsor of the project or the manufacturer or owner of the drug or device under investigation consultant to any of the above? YES NO (If yes, please submit a written standisclosure to the Chairman of the SBS-REC)	n or serv	ve as a

#### RESEARCH PROPOSAL SUMMARY

It is the REC requirement that the composition of the Institutional Review Board (IRB) include individuals with varied backgrounds and education. Investigators are therefore required to attach four (4) copies of a 2-3 page (maximum 4 pages) Research Proposal Summary using the headings provided below in terminology that is understandable across disciplines.

#### 1. RESEARCH QUESTION TO BE ADDRESSED BY THIS PROPOSAL

#### 2. RATIONALE FOR RESEARCH

- Describe <u>briefly</u> the background of the study, and state reasons for conducting it.
- State objectives of study.

#### 3. METHODS

- Study design and rationale for that design. Explain how the study will be performed.
- Population: Sample size, selection and exclusion of subjects, gender. For larger sample sizes on greater than minimal risk studies, provide justification of the sample size.
- Subject's state of physical health. Indicate if healthy, ill, seriously ill or terminally ill.
- Does the study involve any special populations: Subjects will include, minors, fetuses, abortuses, pregnant women, prisoners, mentally retarded, mentally disabled, or none of the above.
- If subjects are from one of the above special populations explain the necessity for including them.
- Specify source of participating subjects, e.g. hospitals, clinics, institutions, prisons, industry, unions, schools, general population, etc. NOTE: If you plan to advertise for patients, the ad must be submitted to the SBS-REC for review and approval prior to its publication and/or posting.
- List all research procedures and/or interventions involving human subjects (when applicable) including tests to be conducted and the analysis of samples (where applicable including where the analysis is to be done if outside the country please justify including how the samples are to be shipped).
- Distinguish procedures which are part of routine care from those that are part of the study

and the expected date of completion and submission to the SBS-REC.

Questionnaire/interview instrument (when applicable)
 If the study includes either of these, a copy of the instrument is to be appended to this application.
 If the instrument is in development stages, provide an outline of the types of questions to be asked

- Methods of intervention Will any new drugs or biologic agents be administered to the subjects, or will previously used agents be used in a new manner? If **yes**, please note that you are also required to file a separate application with the National Drug Authority (NDA) and may not conduct your study without the approval of both the NDA and the SBS-REC. You are also required to complete the relevant part in this application titled "Studies involving the testing of drugs and medical devices".
- Methods for dealing with adverse events
- Methods for dealing with illegal, reportable activities (e.g child abuse)

#### **RISKS / BENEFITS TO SUBJECTS**

- Highlight any potential risks physical, psychological, social, legal, ethical (e.g. confidentiality), or other and assess the likelihood and seriousness of such risks (none, low, moderate, and high). Include the incidence of complications if known. You may use a narrative description if more appropriate or a table with 3 columns (Potential adverse effects, seriousness and likelihood of complications (Incidence if known.)
- Highlight procedures for protecting against or minimizing potential risks.
- If the activity involves women who could become pregnant and is potentially harmful to a fetus, describe steps that will be taken to prevent pregnancy or exclude pregnant women.
- Assess potential benefits to be gained by the individual subject and explain why the benefits outweigh the risks.
- Assess benefits which may accrue to society in general as a result of the planned work.

#### **COMPENSATION/REIMBURSEMENT**

• Will subjects receive any compensation, monetary or other? If monetary, how much? Will subjects be asked to assume any out-of-pocket costs for participating in the research? If yes, what? Identify expenses such as additional transportation, laboratory tests, supplies, cost of study drug if it becomes commercially available, etc.

#### INFORMED CONSENT

- Any kind of contact with human subjects requires a disclosure/consent process.
- Attach a copy of the consent form. Indicate how (verbal or written) informed consent will be obtained (please request for guidelines for implementing informed consent from the SBS-REC Offices).
- If subjects are minors or mentally disabled, describe how and by whom permission will be granted.
- Where will the record of consent be stored? (Consent forms must be kept for three years after the completion of the investigation, unless otherwise stipulated by the SBS-REC).

#### **CONFIDENTIALITY ASSURANCES**

Describe any means by which the subject's personal privacy is to be protected and confidentiality of data maintained. Include information on the following:

- Any sensitive information that will be gathered.
- Plans for record keeping
- Location of the data
- Data security
- Person responsible and telephone number
- Who will have access to the data
- Plans for disposal of the data upon completion of the study

#### **CONFLICT OF INTEREST** (real or apparent)

• Other than the normal scholarly gains, are there any other gains you might receive from taking part in this study?

#### **COLLABORATIVE AGREEMENTS**

• Provide letters of approval from collaborating institutions' IRBs and from other local IRBs from other sites.

#### INTENDED USE OF RESULTS

Include plans for dissemination and utilization of study results

#### **OTHER INFORMATION**:

• Any other information.

<u>Please note</u>: Attach 2 COPIES of the full research proposal. The full proposal should include the following: Title, objectives, background and literature review, methodology (to include research design, subjects and methods, ethical considerations, timetables etc. references, budget etc. Investigators may submit the full proposal in the funding agency format as long as it covers the above headings.

Please also attach copies of **curriculum vitae** for the Principal Investigators and all Co- investigators. The CVs should include the following: Name, Postal address, Employers name and address, Qualifications, Present Position, past research experience (relevant) and Published Papers (relevant). Principal Investigators or co-investigators who would have already submitted their CVs during the current year are exempted from this requirement.

# STUDIES INVOLVING THE TESTING OF DRUGS AND DEVICES DRUG / DEVICE INFORMATION FORM

PROVIDE DOSSIER OR BROCHURE OF INVESTIGATIONAL DRUG/DEVICE

#### **SIGNATURE ASSURANCE SHEET**

## Principal Investigator's Assurance Statement:

I certify that the information given by me is correct to the best of my knowledge; I am familiar with and understand the REC's policy concerning research involving human subjects (CIOMS Guidelines or Helsinki Declaration) and I agree:

(-	Please check all that applies)				
1.	1. To accept responsibility for the scientific and ethical conduct of this research study;				
2.	To obtain prior approval from the SBS-REC as well as the UNCST before amer research protocol or implementing changes in the approved consent form;	nding or altering the			
3.	To immediately report to the SBS-REC and the UNCST any serious adverse real unanticipated effects on subjects which may occur as a result of this study;	ctions and/or			
<ul><li>4.</li><li>5.</li></ul>	☐ To complete and submit the Continuing annual Review Form annually (when dufinal/Study termination form at the end of the proposed study (if applicable). ☐ To submit the final study report to the SBS-REC using a standard form.	ue) as well as the			
Si	gnature	Date			
P	rint name				
	ignature of Co-investigator rint Name	Date			

SUBMIT APPLICATION PACKAGE TO THE SBS-REC OFFICES (The entire application package includes the application form, research proposal summary (2-3 pages), full research proposal (even in funding agency format), consent form and other relevant documents).

\*\*\*\*\*

# RESEARCH AND ETHICS COMMITTEE REVIEW AND ENDORSEMENT REQUIRED

## Statement from the Research Ethics Committee:

The REC will only accept for review and approval research proposals that have been found both scientifically and ethically acceptable in accordance with the Guidelines on Research Ethics Committees.

We the <b>Research Ethics Committee</b> established by						
(Name of Institution	or conducting the research/in which the research is to he conduct	 ed)				
do certify tha	at we have reviewed the research proposal titled					
	submitted by					
We attest to the scientific and ethical merit of this study and the competency of the investigator(s) to conduct the project and do hereby recommend the proposal to the UNCST for approval.						
	<u>SIGNATURES</u>					
Signature		Date				
Ethics Committee representative						
Name (Please Print)			<u> </u>			
Signature: Head of Ethics						
Committee						
(or other authorized signatory)						
Name (Please Print)			<u> </u>			
Contact Tel. Number	<i>:</i>					
E-mail address :						

\*Institution includes Universities, Hospitals, Research Institutes or Companies.

**OFFICIAL STAMP OF INSTITUTION**